CoreCivic (CXW)

consolidated · GAAP

FY2026-Q2 · Period ending Jun 30, 2026

Source: company_financial_results. Reference: 730ffe79-05d5-44fe-b968-02cc04572a9c.

Source status: eligible.

Stated as a priority in 4 of last 4 quarters. Net income increased from $25.1 million in 2025-Q1 to $37.1 million in 2026-Q2, and diluted EPS rose from $0.23 to $0.37 over the same period. Growth was driven by facility activations, acquisitions, and share repurchases. The trajectory shows delivering consistent earnings growth aligned with management's statements.

consolidated · GAAP

FY2026-Q2 · Period ending Jun 30, 2026

Source: stock_quarterly_financials_fmp. Reference: 2026-Q2.

Source status: unverified.

Stated as a priority in 4 of last 4 quarters. Operating margins showed mixed trends: 22.4% in 2026-Q2 down from 26.1% in 2025-Q2 due to nonrecurring credits, but facility operating margin improved to 24.0% in 2026-Q1 from 23.6% in 2025-Q1. Activations contributed $21.1 million operating income in 2026-Q2. The trajectory shows delivering operational improvements with some margin pressure from start-up costs.

consolidated · GAAP

FY2026-Q2 · Period ending Jun 30, 2026

Source: company_financial_results. Reference: 730ffe79-05d5-44fe-b968-02cc04572a9c.

Source status: eligible.

Stated as a priority in 4 of last 4 quarters. Revenue grew from $488.6 million in 2025-Q1 to $684.9 million in 2026-Q2, driven by activations of previously idle facilities and the acquisition of Clinical Solutions Pharmacy. Management consistently emphasized these drivers, and the financials show delivering growth aligned with this priority.

Stated as a priority in 3 of last 3 quarters. Management increased share repurchase authorization from $700 million to $1.2 billion in 2026-Q2 and repurchased 28.1 million shares at a cost of $444.2 million through 2026-Q1. Weighted average diluted shares outstanding decreased 8.9% year-over-year in 2026-Q2. The trajectory shows delivering disciplined capital allocation through share repurchases.